# CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

> **NCT04220476** · PHASE2 · WITHDRAWN · sponsor: **Weill Medical College of Cornell University**

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
- **DRUG:** Letrozole 2.5Mg Tab
- **DRUG:** Palbociclib 125mg

## Key facts

- **NCT ID:** NCT04220476
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Initiating a new study with revised Statistics.
- **Last updated:** 2020-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220476, "CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04220476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*